New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026
Eisai and Biogen announced three-year real-world findings from the LEADER study of 560 patients showing LEQEMBI reduced progression to moderate/severe Alzheimer's disease by 76% compared to natural history controls. The analysis demonstrated 81% of patients remained stable or improved, 77% achieved amyloid-negative status, and subcutaneous maintenance therapy showed favorable safety profiles with no ARIA events reported.


